on major coronary events in hypercholesterolaemic patients (JELIS): a Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded. Significant reduction in residual risk in patients treated with statins. Results from the JELIS (Japan EPA Lipid Intervention Study) trial. EPA may have beneficial.

Author: Nabei Shaktirr
Country: Angola
Language: English (Spanish)
Genre: Marketing
Published (Last): 24 March 2013
Pages: 326
PDF File Size: 1.2 Mb
ePub File Size: 15.55 Mb
ISBN: 215-5-34121-727-5
Downloads: 23286
Price: Free* [*Free Regsitration Required]
Uploader: Tulkree

The primary, secondary, and tertiary adjudicated endpoint analyses were validated by the data monitoring committee independent statistician. EPA is a promising treatment for prevention of major coronary events, and especially non-fatal coronary events, in Japanese hypercholesterolaemic patients.

Other cardiovascular outcomes trials that studied fish oil or mixtures of omega-3 acids that include the omega-3 acid, DHA, have reported negligible impact on cardiovascular events. Icosapent tsudy, a pure ethyl ester of eicosapentaenoic acid: Watch the national commercial. By working together and supporting these efforts, inside and outside of the company, Amarin can empower, share and learn as it strides toward the unified goal of excellence—and beyond.

Overall adverse event rates were similar across treatment groups. CI denotes confidence interval. The median age at baseline was 64 years range: Unstable angina and non-fatal coronary events were also significantly reduced in the EPA group. The omega-3 fatty acid mixtures studied in such other outcomes trials were primarily comprised of EPA and docosahexaenoic acid DHA typically, approximately mg total per 1 gram capsule and also typically included a number of other omega-3 and omega-6 stud, as well as other constituents.

Curves were visually truncated at 5. This information on inflammatory markers cannot be used in isolation. The primary endpoint was any major coronary event, including sudden cardiac death, fatal and non-fatal myocardial infarction, and other non-fatal events including unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting. Am J Cardiovasc Drugs. We encourage you to check that for yourself.


VASCEPA® (icosapent ethyl) | REDUCE-IT™ Results Announced

These observations suggest that at least some of the impact of VASCEPA on the reduction in ischemic events may be explained by metabolic effects other than triglyceride lowering. GISSI-P is an open-label outcomes trial jeliss g omega-3 fatty acid mixtureconducted in Shudy, that supported the hypothesis that omega-3 fatty acids likely exert their cardioprotective effects through nonlipid-mediated mechanisms. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia [published online ahead of print November 10, ].

This site uses cookies to give you the best possible experience. This offer is not valid for those patients under 18 years of age or patients whose plans do not permit use of a copay jels. GISSI-P did not suggest an effect on the incidence of nonfatal cardiovascular events and the effects of omega-3 fatty acids on lipids, including serum TGs, were negligible.

Mineral oil placebo consideration and analysis. At mean follow-up of 4.

Offer good through December 31, N Engl J Med. Only subjects with non-missing baseline and week 12 values are included. Sudden cardiac death and coronary death did not differ between groups.

Amarin, through its dedicated team of professionals, constantly seeks to improve patient care through its actions and products while also striving to continuously improve along the way.

Kaplan-Meier estimates of the incidence of the primary endpoint of coronary events occurring in the group of all patients.

About Amarin

Further detailed data assessment by Amarin and regulatory authorities will continue and take several months to complete and record The final evaluation of the totality of the efficacy and safety data from REDUCE-IT may include some or all of the following, as well as other considerations: Void where prohibited by law, taxed, or restricted.


The changes in the major lipoprotein lipid parameters for the groups receiving VASCEPA plus statin or placebo plus statin are shown in the table. The study was registered at ClinicalTrials. Patients were randomly assigned 1: United States Food and Drug Administration et al.

Not for use by residents of VT, nor medical professionals licensed in VT. Most patients at baseline were taking at least one other cardiovascular medication including anti-platelet agents Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Wtudy additional baseline risk factors included hypertension The Kaplan-Meier estimates of the cumulative incidence of the primary and key secondary composite endpoints over time are shown in Figure 1 and Figure 2 below.

Serum LDL cholesterol was not a significant factor in a reduction of risk for major coronary events. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: The trial population was Patients enrolled were sttudy with statin therapy at baseline with most Prespecified hierarchical testing of other secondary endpoints revealed significant reductions in the following:.

Eligible patients include those who participate in commercial insurance, through a healthcare exchange, or pay cash. P values for Lp-PLA 2a secondary endpoint, were adjusted for multiple comparisons; all other endpoints are exploratory. Adapted from Yokoyama sstudy al, Figure 3: Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: This focus includes a commitment to research and education in cardiovascular health.

No head-to-head cardiovascular outcomes study of EPA vs a mixture of omega-3 acids has been conducted.